黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

WT1 regulates cyclin A1 expression in K562 cells

Oncol Rep. 2019; 
Pandey S, Moazam M, Ghimirey N, Kuerbitz SJ, Fraizer GC.
Products/Services Used Details Operation
Recombinant Proteins … and probed overnight with anti-WT1 at a 1:1,000 dilution (#5G11A5; ab201948; Abcam, Cambridge, MA, USA), anti-CCNA1 at a 1:1,000 dilution (#B882; 556600; BD Pharmingen, San Diego, CA, USA) or anti-actin at a 1:3,000 dilution (#A00702; Genscript, Piscataway, NJ, USA … Get A Quote

摘要

The restricted expression of Wilms tumor 1 (WT1) and cyclin A1 (CCNA1) in normal tissues, as opposed to their abnormal expression in leukemia demonstrates the applicability of WT1 and CCNA1 as cancer antigens for immunotherapy, and as markers for prognosis and relapse. In this study, the WT1 and CCNA1 mRNA levels were found to be elevated in bone marrow samples from pediatric acute promyelocytic leukemia (APL or AML‑M3) patients, and to be quite varied in pediatric acute lymphocytic leukemia (ALL) patients, compared to non‑leukemic bone marrow controls. Consistent with the observed upregulation of both WT1 and CCNA1 in APL, WT1 overexpression elevated the CCNA1 mRNA levels in K562 leukemia cells. Treatmen... More

关键词